FR2825093B1 - Polypeptide reagissant avecles anticorps de patients infectes par vhc et utilisations - Google Patents

Polypeptide reagissant avecles anticorps de patients infectes par vhc et utilisations

Info

Publication number
FR2825093B1
FR2825093B1 FR0106935A FR0106935A FR2825093B1 FR 2825093 B1 FR2825093 B1 FR 2825093B1 FR 0106935 A FR0106935 A FR 0106935A FR 0106935 A FR0106935 A FR 0106935A FR 2825093 B1 FR2825093 B1 FR 2825093B1
Authority
FR
France
Prior art keywords
hcv
antibodies
patients infected
polypeptide
reacting
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
FR0106935A
Other languages
English (en)
Other versions
FR2825093A1 (fr
Inventor
Reynaud Colette Jolivet
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Biomerieux SA
Original Assignee
Biomerieux SA
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Biomerieux SA filed Critical Biomerieux SA
Priority to FR0106935A priority Critical patent/FR2825093B1/fr
Priority to PCT/FR2002/001797 priority patent/WO2002096941A2/fr
Publication of FR2825093A1 publication Critical patent/FR2825093A1/fr
Application granted granted Critical
Publication of FR2825093B1 publication Critical patent/FR2825093B1/fr
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/24011—Flaviviridae
    • C12N2770/24211—Hepacivirus, e.g. hepatitis C virus, hepatitis G virus
    • C12N2770/24222—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Virology (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Genetics & Genomics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Peptides Or Proteins (AREA)
FR0106935A 2001-05-28 2001-05-28 Polypeptide reagissant avecles anticorps de patients infectes par vhc et utilisations Expired - Fee Related FR2825093B1 (fr)

Priority Applications (2)

Application Number Priority Date Filing Date Title
FR0106935A FR2825093B1 (fr) 2001-05-28 2001-05-28 Polypeptide reagissant avecles anticorps de patients infectes par vhc et utilisations
PCT/FR2002/001797 WO2002096941A2 (fr) 2001-05-28 2002-05-28 Polypeptide reagissant avec les anticoprs de patients infectes par le vhc et utilisations

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
FR0106935A FR2825093B1 (fr) 2001-05-28 2001-05-28 Polypeptide reagissant avecles anticorps de patients infectes par vhc et utilisations

Publications (2)

Publication Number Publication Date
FR2825093A1 FR2825093A1 (fr) 2002-11-29
FR2825093B1 true FR2825093B1 (fr) 2003-07-18

Family

ID=8863683

Family Applications (1)

Application Number Title Priority Date Filing Date
FR0106935A Expired - Fee Related FR2825093B1 (fr) 2001-05-28 2001-05-28 Polypeptide reagissant avecles anticorps de patients infectes par vhc et utilisations

Country Status (2)

Country Link
FR (1) FR2825093B1 (fr)
WO (1) WO2002096941A2 (fr)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8535672B2 (en) 2002-04-04 2013-09-17 Yissum Research Development Of The Hebrew University Of Jerusalem Broad-spectrum in-vivo effective superantigen toxin antagonists based on the interaction between CD28 and the superantigen and uses thereof
WO2004087754A1 (fr) * 2003-04-03 2004-10-14 Yissum Research Development Company Of The Hebrew University Of Jerusalem Antagonistes a large spectre efficaces in vivo de la toxine d'un superantigene reposant sur l'interaction entre la molecule cd28 et le superantigene, et utilisations correspondantes
KR100958840B1 (ko) 2007-08-28 2010-05-24 단국대학교 산학협력단 항－테나신 c 펩타이드 및 그의 용도
WO2016069762A2 (fr) 2014-10-29 2016-05-06 Abbott Laboratories Analyses consistant à détecter des anticorps anti-vhc selon l'invention en utilisant des peptides de capture ns3

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK0992580T3 (da) * 1993-11-04 2005-07-11 Innogenetics Nv Epitoper på human T-celler, som er immundominante for hepatitis C-virus
FR2737209B1 (fr) * 1995-07-25 1997-09-19 Bio Merieux Peptide capable d'etre reconnu par des anticorps reconnaissant l'antigene c33 du virus de l'hepatite c

Also Published As

Publication number Publication date
WO2002096941A2 (fr) 2002-12-05
FR2825093A1 (fr) 2002-11-29

Similar Documents

Publication Publication Date Title
FR16C1012I2 (fr) Utilisation therapeutique d'anticorps anti-cs1
DE60227300D1 (de) Strukturen von anschlusselementen und anzuschliessende komponente
FR14C0007I2 (fr) Remodelage et glycoconjugaison de peptides
DK1242460T3 (da) Immobilisering af proteiner ved hjælp af et polypeptidsegment
ATE421973T1 (de) Inzektizide proteinen von bacillus thuringiensis
DE60206344D1 (de) Baueinheit von Leuchten und Zubehör
DE60223502D1 (de) Medizinische schlinge
ATE276762T1 (de) Stabile lyophilisierte pharmazeutische zubereitungen von mono- oder polykonalen antikörpern
DE60218695D1 (de) Biosensoren und messverfahren
AU2002351239A8 (en) Antibody to latent membrane proteins and uses thereof
DE60026022D1 (de) Fluor enthaltende allylether und höhere homologe
DE60223841D1 (de) Medizinische verwendung von gsk3-hemmenden oxindolderivaten
DE19882430T1 (de) Korrektur von Emissions-Kontamination und Totzeitverlust
DE60225014D1 (de) Pharmazeutische zusammensetzungen von amlodipin und atorvastatin
AU2002365404A8 (en) Solid-phase immobilization of proteins and peptides
ATE401339T1 (de) Mischungen von cyclosporin-analogen und ihre verwendung als immunmodulatoren
DE50111779D1 (de) Selbstnivellierender Zusammenbau von Gabelkopf und Zugvorrichtung
FR2825093B1 (fr) Polypeptide reagissant avecles anticorps de patients infectes par vhc et utilisations
DE60031826D1 (de) Trennung von Viren und Nachweis von Viren
HUP0201087A3 (en) Hepatitis c antigen-antibody combination assay for the early detection of infection
DE60203475D1 (de) Drosselklappe und Drossel
DE60238856D1 (de) Anthranilsäureamide und ihre pharmazeutische verwendung
MA27184A1 (fr) Dosage d'anticorps anti-ingap
DE60232155D1 (de) Humaner rekombinanter antikörper gegen das hepatitis c (hcv) nichtstrukturelles ns3 protein, nukleinsäure und deren verwendungen
NO20024325D0 (no) Rensede hepatitt C-viruskappeproteiner for diagnostisk og terapeutisk anvendelse

Legal Events

Date Code Title Description
ST Notification of lapse